Immunotherapy has transformed cancer treatment, but its effectiveness varies widely among patients, with many not responding and others developing resistance after initial success. Identifying likely responders beforehand remains a major clinical challenge. Now, a novel liquid biopsy may offer a solution, providing a minimally invasive method to predict immunotherapy response in patients with advanced lung cancer.
The test analyzes circulating tumor DNA (ctDNA) in blood samples, detecting genetic alterations that correlate with response to immune checkpoint inhibitors. According to a recent study, patients with certain ctDNA profiles showed significantly better progression-free survival when treated with immunotherapy, while those with different profiles derived little benefit. This could enable oncologists to tailor treatments more precisely, sparing non-responders from unnecessary side effects and costly therapies.
The implications extend beyond patient care. For companies developing immunotherapies, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), this liquid biopsy could streamline clinical trials by enriching patient populations most likely to respond, accelerating drug development and reducing costs. By using the test as a companion diagnostic, developers can identify suitable candidates early, enhancing trial efficiency and improving success rates.
Moreover, the liquid biopsy offers a dynamic tool to monitor treatment response over time, detecting emerging resistance before clinical progression. This allows for timely adjustments, potentially extending the duration of benefit. The test's non-invasive nature is a significant advantage over tissue biopsies, which are often difficult to obtain in lung cancer patients and may not reflect the tumor's evolving genetic landscape.
Experts highlight that while the findings are promising, further validation in larger, prospective studies is needed before the test becomes standard practice. However, the potential to personalize immunotherapy is a step forward in precision oncology. As research continues, such biomarkers could become integral to treatment decision-making, ensuring that the right patients receive the right drugs at the right time.
For more insights into the latest developments in biotechnology and life sciences, stay informed with industry updates from BioMedWire, a leading communications platform covering these sectors.
